{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031636","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.493394+00:00","generated_at":"2026-06-21T21:41:55.525421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon Q3 net loss $6.1M ($0.87/sh); PLACCINE NHP data shows similar protection to mRNA vaccine","bullets":["Net loss of $6.1M ($0.87 per share) vs $5.4M ($0.94 per share) in Q3 2021; operating expenses rose 21% to $6.3M.","Cash and investments of $43.4M; expects cash runway into 2025.","Phase I/II OVATION 2 study with GEN-1 fully enrolled (110 patients); topline results expected H1 2024.","PLACCINE NHP study: viral clearance >90% in vaccinated vs controls; protection comparable to commercial mRNA vaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031636","json":"https://secwatch.observer/filing/0001493152-22-031636.json","markdown":"https://secwatch.observer/filing/0001493152-22-031636.md","text":"https://secwatch.observer/filing/0001493152-22-031636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/0001493152-22-031636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:41:55.525421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"212ab0d44b552d682aa4815160655df64908f47f","claim":"Imunon, Inc. reported financial results for the three-month and nine-month periods ended September 30, 2022.","evidence_excerpt":"IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (November 14, 2022) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three-month and nine-month periods ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315222031636/0001493152-22-031636-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three-month and nine-month periods ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}